N. Engl. J. Med. 2012-04-19
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
ABSTRACT
BACKGROUND
Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder cancer. In other disease sites, synchronous chemoradiotherapy has been associated with increased local control and improved survival, as compared with radiotherapy alone.
METHODS
In this multicenter, phase 3 trial, we randomly assigned 360 patients with muscle-invasive bladder cancer to undergo radiotherapy with or without synchronous chemotherapy. The regimen consisted of fluorouracil (500 mg per square meter of body-surface area per day) during fractions 1 to 5 and 16 to 20 of radiotherapy and mitomycin C (12 mg per square meter) on day 1. Patients were also randomly assigned to undergo either whole-bladder radiotherapy or modified-volume radiotherapy (in which the volume of bladder receiving full-dose radiotherapy was reduced) in a partial 2-by-2 factorial design (results not reported here). The primary end point was survival free of locoregional disease. Secondary end points included overall survival and toxic effects.
RESULTS
At 2 years, rates of locoregional disease-free survival were 67% (95% confidence interval [CI], 59 to 74) in the chemoradiotherapy group and 54% (95% CI, 46 to 62) in the radiotherapy group. With a median follow-up of 69.9 months, the hazard ratio in the chemoradiotherapy group was 0.68 (95% CI, 0.48 to 0.96; P=0.03). Five-year rates of overall survival were 48% (95% CI, 40 to 55) in the chemoradiotherapy group and 35% (95% CI, 28 to 43) in the radiotherapy group (hazard ratio, 0.82; 95% CI, 0.63 to 1.09; P=0.16). Grade 3 or 4 adverse events were slightly more common in the chemoradiotherapy group than in the radiotherapy group during treatment (36.0% vs. 27.5%, P=0.07) but not during follow-up (8.3% vs. 15.7%, P=0.07).
CONCLUSIONS
Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with radiotherapy alone, with no significant increase in adverse events. (Funded by Cancer Research U.K.; BC2001 Current Controlled Trials number, ISRCTN68324339.).
Related Questions
In the definitive setting, and would that change if cystecomy was planned if there was a complete response after CRT? (similar to TCC paradigm).
New answer by Radiation Oncologist at Washington University School of Medicine (June 10, 2014)
There is a recent series (May 2014) and review published in Practial Radiation Oncology from Memorial Sloan Kettering. While they don't describe a dose response given the sma...
I've heard justification for treating the whole bladder to 60-64 Gy based on the UK MRC study (James et al. NEJM 2012 and Huddart et al. IJROBP 2013) ...
New answer by Radiation Oncologist at Cedars-Sinai Medical Center (May 7, 2015)
I agree with @Anthony L. Zietman about whole vs. partial bladder "cone-down", although in my experience I'm much less like than @Anthony L. Zietman to treat partial ...
Realistically, there will always be some (hopefully small) inconsistency with bladder filling, and thus some small bowel could easily receive &ge...
New answer by Radiation Oncologist at University of Utah School of Medicine (April 9, 2015)
This is an excellent question, and something we struggle with. DVH parameters are important considerations, but I also feel that sometimes we put too much emphasis on dose co...
Would you recommend radiation and/or systemic therapy? If you would irradiate, what would your fields/volumes look like?
New comment by Medical Oncologist at University of Washington School of Medicine ( December 28, 2017)
Great answer by the excellent @Omar Y. Mian. The SOC is radical cystectomy with bilateral pelvic LN dissection; however, if medical inoperable, clinical trial is the preferred...
Assuming you are treating whole bladder only with concurrent chemotherapy, when would you recommend hypofractionated radiation (20 fractions) vs stand...
New answer by Radiation Oncologist at Cedars-Sinai Medical Center (January 19, 2018)
In the BC2001 study (James N, NEJM 366:1477, 2012) that showed a benefit to chemoradiotherapy over radiotherapy alone, two fractionation schemes were allowed: 64 Gy in 32 frac...
New comment by Radiation Oncologist at Dana-Farber Cancer Institute, Harvard Medical School ( September 2, 2019)
I've had several follow-up questions and comments, particularly relating to small bowel doses, so here are some additional thoughts and data.
Limiting small bowel dose is the...
Do you routinely include pelvic lymph nodes, prostatic urethra, and prostate?
New comment by Radiation Oncologist at UC San Diego ( January 11, 2020)
I share your concern. I take solace in the data from the studies, including BC2001. But I do keep hot spots out of the small bowel and will happily limit the boost-level volum...
Can chemoradiation be curative without maximal debulking TURBT?
New comment by Radiation Oncologist at National Institutes of Health Clinical Center ( October 18, 2023)
In a retrospective publication from MRG, the hazard ratio for complete vs. incomplete TUBRT on multivariable Cox regression analysis was 0.72 [95% CI: 0.55-0.96] for bladder-i...
The recommended concurrent chemotherapy regimens (cisplatin/paclitaxel and cisplatin/FU) in NCCN are based on BID fractionation of radiation as in RTO...
New comment by Radiation Oncologist at Dana-Farber Cancer Institute, Harvard Medical School ( September 23, 2021)
SWOG/NRG 1806, the currently accruing Phase III RCT of bladder-preserving trimodality therapy with vs without concurrent and adjuvant atezolizumab, allows (and stratifies by) ...
New answer by Medical Oncologist at AdventHealth Cancer Institute (November 1, 2022)
While data for pure non-urothelial histology and trimodality therapy (TMT) are lacking, a retrospective study suggests that variant urothelial carcinoma (VUC, urothelial carci...